| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma in adults. |
|
Medicine details |
|
| Medicine name | ipilimumab (Yervoy®) |
| Formulation | 5 mg/ml concentrate for solution for infusion |
| Reference number | 172 |
| Indication | Treatment of advanced (unresectable or metastatic) melanoma in adults who have received prior therapy |
| Company | Bristol-Myers Squibb Pharmaceuticals Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 01/06/2011 |
| NICE guidance | TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma in adults |